Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D0E3BH
|
|||
Former ID |
DAP000469
|
|||
Drug Name |
Ridogrel
|
|||
Synonyms |
Ibidel; R-68070; Ridogrel (USAN/INN); 5-[(E)-[pyridin-3-yl-[3-(trifluoromethyl)phenyl]methylidene]amino]oxypentanoic acid
Click to Show/Hide
|
|||
Drug Type |
Small molecular drug
|
|||
Indication | Acute myocardial infarction [ICD-11: BA41; ICD-9: 410] | Approved | [1] | |
Therapeutic Class |
Gastrointestinal Agents
|
|||
Structure |
Download2D MOL |
|||
Formula |
C18H17F3N2O3
|
|||
Canonical SMILES |
C1=CC(=CC(=C1)C(F)(F)F)C(=NOCCCCC(=O)O)C2=CN=CC=C2
|
|||
InChI |
1S/C18H17F3N2O3/c19-18(20,21)15-7-3-5-13(11-15)17(14-6-4-9-22-12-14)23-26-10-2-1-8-16(24)25/h3-7,9,11-12H,1-2,8,10H2,(H,24,25)/b23-17+
|
|||
InChIKey |
GLLPUTYLZIKEGF-HAVVHWLPSA-N
|
|||
CAS Number |
CAS 110140-89-1
|
|||
PubChem Compound ID | ||||
PubChem Substance ID | ||||
ChEBI ID |
CHEBI:135542
|
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Thromboxane A2 receptor (TBXA2R) | Target Info | Binder | [2] |
KEGG Pathway | Calcium signaling pathway | |||
Neuroactive ligand-receptor interaction | ||||
Platelet activation | ||||
Reactome | Prostanoid ligand receptors | |||
G alpha (q) signalling events | ||||
G alpha (12/13) signalling events | ||||
Thromboxane signalling through TP receptor | ||||
WikiPathways | GPCRs, Class A Rhodopsin-like | |||
Gastrin-CREB signalling pathway via PKC and MAPK | ||||
Small Ligand GPCRs | ||||
Signal amplification | ||||
GPCR ligand binding | ||||
GPCR downstream signaling |
References | Top | |||
---|---|---|---|---|
REF 1 | Inhibition of cytochromes p450: existing and new promising therapeutic targets. Drug Metab Rev. 2007;39(2-3):481-99. | |||
REF 2 | Chronic ouabain treatment exacerbates blood pressure elevation in spontaneously hypertensive rats: the role of vascular mechanisms. J Hypertens. 2009 Jun;27(6):1233-42. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.